董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Murray | 男 | Director, Chief Executive Officer and President | 64 | 75.03万美元 | 未持股 | 2023-03-10 |
| Robert Kamen | 男 | Director | 78 | 3.38万美元 | 未持股 | 2023-03-10 |
| Jigar Raythatha | 男 | Chairman of the Board | 46 | 未披露 | 未持股 | 2023-03-10 |
| Robert Iannone | 男 | Director | 56 | 未披露 | 未持股 | 2023-03-10 |
| Luis Diaz, Jr. | 男 | Director | 52 | 24.17万美元 | 未持股 | 2023-03-10 |
| Luisa Salter Cid | 男 | Director | 58 | 未披露 | 未持股 | 2023-03-10 |
| Perry A. Karsen | 男 | Director | 67 | 8.13万美元 | 未持股 | 2023-03-10 |
| Barbara Duncan | 女 | Director | 58 | 5.16万美元 | 未持股 | 2023-03-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Murray | 男 | Director, Chief Executive Officer and President | 64 | 75.03万美元 | 未持股 | 2023-03-10 |
| Kim C. Drapkin | 女 | Chief Financial Officer and Treasurer | 55 | 87.52万美元 | 未持股 | 2023-03-10 |
| Elizabeth G. Trehu | 女 | Chief Medical Officer | 62 | 51.36万美元 | 未持股 | 2023-03-10 |
| Hugh M. Cole | 男 | Chief Operating Officer | 57 | 217.47万美元 | 未持股 | 2023-03-10 |
董事简历
中英对照 | 中文 | 英文- Richard Murray
-
Richard Murray，自2014年7月以来，Murray一直担任Jounce Therapeutics，Inc.股份有限公司总裁、首席执行官以及Jounce ThrapeuticS，Inc.股份有限公司董事会成员。在加入Jounce之前，Murray博士于2009年至2014年6月期间担任默克公司（Merck&Co.）生物制品和疫苗研发高级副总裁，该公司是一家全球医疗保健公司，他负责生物制剂和疫苗的研发，包括默克的癌症免疫治疗管道。自2019年6月以来，他一直担任私人生物技术公司Platelet Biogenesis，Inc.的董事。Murray博士他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位，以及马萨诸塞大学（the University of Massachusetts，位于阿默斯特）的微生物学学士学位。
Richard Murray,Ph.D. —Dr. Murray has served as Jounce Therapeutics, Inc. president, chief executive officer and a member of Jounce Therapeutics, Inc. board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. Since June 2019, he has served as a director of Platelet Biogenesis, Inc., a private biotechnology company. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst. - Richard Murray，自2014年7月以来，Murray一直担任Jounce Therapeutics，Inc.股份有限公司总裁、首席执行官以及Jounce ThrapeuticS，Inc.股份有限公司董事会成员。在加入Jounce之前，Murray博士于2009年至2014年6月期间担任默克公司（Merck&Co.）生物制品和疫苗研发高级副总裁，该公司是一家全球医疗保健公司，他负责生物制剂和疫苗的研发，包括默克的癌症免疫治疗管道。自2019年6月以来，他一直担任私人生物技术公司Platelet Biogenesis，Inc.的董事。Murray博士他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位，以及马萨诸塞大学（the University of Massachusetts，位于阿默斯特）的微生物学学士学位。
- Richard Murray,Ph.D. —Dr. Murray has served as Jounce Therapeutics, Inc. president, chief executive officer and a member of Jounce Therapeutics, Inc. board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. Since June 2019, he has served as a director of Platelet Biogenesis, Inc., a private biotechnology company. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
- Robert Kamen
-
Robert Kamen自2022年2月起，一直是Third Rock Ventures，LLC（TRV）的顾问合伙人，他曾于2017年至2022年1月担任TRV的风险合伙人，并于2010年至2017年担任TRV常驻企业家。Kamen博士担任EpimAb Biotherapeutics，Inc.（一家专门从事双特异性抗体开发的临床阶段生物技术公司）和Harbour BioMed（一家全球临床阶段生物制药公司）的董事会成员。2015年至2020年5月，他担任免疫肿瘤学公司Neon Therapeutics，Inc.的董事会成员。Kamen博士拥有哈佛大学生物化学和分子生物学博士学位和Amherst College生物物理学士学位。
Robert Kamen,Ph.D. —Dr. Kamen has been an advisory partner at Third Rock Ventures, LLC, or TRV, since February 2022, and he previously served as a venture partner at TRV from 2017 through January 2022 and as an entrepreneur-in-residence at TRV from 2010 through 2017. Dr. Kamen serves on the boards of directors of EpimAb Biotherapeutics, Inc., a clinical-stage biotechnology company specializing in bispecific antibody development, and Harbour BioMed, a global clinical-stage biopharmaceutical company. He served on the board of directors of Neon Therapeutics, Inc., an immuno-oncology company, from 2015 through May 2020. Dr. Kamen holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.S. in biophysics from Amherst College. - Robert Kamen自2022年2月起，一直是Third Rock Ventures，LLC（TRV）的顾问合伙人，他曾于2017年至2022年1月担任TRV的风险合伙人，并于2010年至2017年担任TRV常驻企业家。Kamen博士担任EpimAb Biotherapeutics，Inc.（一家专门从事双特异性抗体开发的临床阶段生物技术公司）和Harbour BioMed（一家全球临床阶段生物制药公司）的董事会成员。2015年至2020年5月，他担任免疫肿瘤学公司Neon Therapeutics，Inc.的董事会成员。Kamen博士拥有哈佛大学生物化学和分子生物学博士学位和Amherst College生物物理学士学位。
- Robert Kamen,Ph.D. —Dr. Kamen has been an advisory partner at Third Rock Ventures, LLC, or TRV, since February 2022, and he previously served as a venture partner at TRV from 2017 through January 2022 and as an entrepreneur-in-residence at TRV from 2010 through 2017. Dr. Kamen serves on the boards of directors of EpimAb Biotherapeutics, Inc., a clinical-stage biotechnology company specializing in bispecific antibody development, and Harbour BioMed, a global clinical-stage biopharmaceutical company. He served on the board of directors of Neon Therapeutics, Inc., an immuno-oncology company, from 2015 through May 2020. Dr. Kamen holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.S. in biophysics from Amherst College.
- Jigar Raythatha
-
Jigar Raythatha自2017年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Raythatha先生曾于2012年12月至2017年2月担任生物技术公司JounceTherapeutics，Inc.的首席商务官，在那里他帮助将公司从成立之初建立为公开交易的研究与开发组织。此前，他曾担任我们的公司发展主管（从2009年3月到2013年2月），在那里他曾领导业务发展、战略、计划和联盟管理职能。在担任公司发展主管之前，Raythatha先生于2005年加入Red Abbey Venture Partners，LLC，并于2005年至2007年担任考夫曼研究员，于2007年至2009年担任负责人，并于2009年担任风险合伙人。加入Red Abbey Venture Partners之前，Raythatha从1999年到2003年在BiogenInc.担任多个业务开发、商业和项目管理职位。他在哥伦比亚大学（Columbia University）获得工商管理硕士学位，在罗格斯大学（Rutgers University）获得生物化学和经济学学士学位。
Jigar Raythatha has served as our President and Chief Executive Officer and as a member of our Board of Directors since March 2017. Mr. Raythatha previously served as Chief Business Officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017 where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our Head of Corporate Development from March 2009 to February 2013 where he led business development, strategy and program and alliance management functions. Prior to serving as our Head of Corporate Development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman Fellow from 2005 to 2007 principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University. - Jigar Raythatha自2017年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Raythatha先生曾于2012年12月至2017年2月担任生物技术公司JounceTherapeutics，Inc.的首席商务官，在那里他帮助将公司从成立之初建立为公开交易的研究与开发组织。此前，他曾担任我们的公司发展主管（从2009年3月到2013年2月），在那里他曾领导业务发展、战略、计划和联盟管理职能。在担任公司发展主管之前，Raythatha先生于2005年加入Red Abbey Venture Partners，LLC，并于2005年至2007年担任考夫曼研究员，于2007年至2009年担任负责人，并于2009年担任风险合伙人。加入Red Abbey Venture Partners之前，Raythatha从1999年到2003年在BiogenInc.担任多个业务开发、商业和项目管理职位。他在哥伦比亚大学（Columbia University）获得工商管理硕士学位，在罗格斯大学（Rutgers University）获得生物化学和经济学学士学位。
- Jigar Raythatha has served as our President and Chief Executive Officer and as a member of our Board of Directors since March 2017. Mr. Raythatha previously served as Chief Business Officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017 where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our Head of Corporate Development from March 2009 to February 2013 where he led business development, strategy and program and alliance management functions. Prior to serving as our Head of Corporate Development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman Fellow from 2005 to 2007 principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University.
- Robert Iannone
-
Robert Iannone自2018年3月起担任公司研发主管和首席医疗官，在加入公司之前，Iannone博士于2014年7月至2018年4月受聘于阿斯利康，担任高级副总裁和免疫肿瘤学主管，全球药物开发和全球产品Vice President。在加入阿斯利康（AstraZeneca）之前，Iannone博士于2004年至2017年在默克（Merck）担任职务，职责不断增加，最终担任肿瘤临床开发执行董事兼部门主管。Iannone博士是一名儿科医生和儿科血液学家-肿瘤学家。Iannone博士毕业于美国天主教大学（Catholic University of America’；89），是耶鲁医学院（Yale Medical School）的红衣主教吉本斯学者（’；94）。
Robert Iannone,was appointed Jazz Pharmaceuticals Public Limited Company Executive Vice President, Global Head of Research and Development as of May 2019. He also served as Jazz Pharmaceuticals Public Limited Company Chief Medical Officer from December 2019 until October 2021. From April 2018 until May 2019, Dr. Iannone served as Head of Research and Development and Chief Medical Officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of Senior Vice President and Head of Immuno-oncology, Global Medicines Development and the Global Products Vice President at AstraZeneca plc, a global science-led biopharmaceutical company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global biopharmaceutical company, culminating in his role as Executive Director and Section Head of Oncology Clinical Development. From 2001 to 2004, he served as Assistant Professor of Pediatrics and from 2004 to 2012 as Adjunct Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Iannone has been serving on the board of directors of iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, since May 2021, and on the Cancer Steering Committee of the Foundation for the National Institutes of Health since 2011. Dr. Iannone previously served as director of Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, from January 2020 to May 2023. Dr. Iannone received a B.S. from The Catholic University of America, an M.D. from Yale University and an M.S.C.E. from University of Pennsylvania and completed his residency in Pediatrics and fellowship in Pediatric Hematology-Oncology at Johns Hopkins University. - Robert Iannone自2018年3月起担任公司研发主管和首席医疗官，在加入公司之前，Iannone博士于2014年7月至2018年4月受聘于阿斯利康，担任高级副总裁和免疫肿瘤学主管，全球药物开发和全球产品Vice President。在加入阿斯利康（AstraZeneca）之前，Iannone博士于2004年至2017年在默克（Merck）担任职务，职责不断增加，最终担任肿瘤临床开发执行董事兼部门主管。Iannone博士是一名儿科医生和儿科血液学家-肿瘤学家。Iannone博士毕业于美国天主教大学（Catholic University of America’；89），是耶鲁医学院（Yale Medical School）的红衣主教吉本斯学者（’；94）。
- Robert Iannone,was appointed Jazz Pharmaceuticals Public Limited Company Executive Vice President, Global Head of Research and Development as of May 2019. He also served as Jazz Pharmaceuticals Public Limited Company Chief Medical Officer from December 2019 until October 2021. From April 2018 until May 2019, Dr. Iannone served as Head of Research and Development and Chief Medical Officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of Senior Vice President and Head of Immuno-oncology, Global Medicines Development and the Global Products Vice President at AstraZeneca plc, a global science-led biopharmaceutical company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global biopharmaceutical company, culminating in his role as Executive Director and Section Head of Oncology Clinical Development. From 2001 to 2004, he served as Assistant Professor of Pediatrics and from 2004 to 2012 as Adjunct Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Iannone has been serving on the board of directors of iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, since May 2021, and on the Cancer Steering Committee of the Foundation for the National Institutes of Health since 2011. Dr. Iannone previously served as director of Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, from January 2020 to May 2023. Dr. Iannone received a B.S. from The Catholic University of America, an M.D. from Yale University and an M.S.C.E. from University of Pennsylvania and completed his residency in Pediatrics and fellowship in Pediatric Hematology-Oncology at Johns Hopkins University.
- Luis Diaz, Jr.
-
LuisDiaz，Jr.，医学博士，迪亚兹博士自2016年12月起担任实体瘤肿瘤科主任兼纪念斯隆·凯特琳癌症中心教员。从2004年到2016年12月，Diaz博士是约翰霍普金斯大学医学院的教员和医生。Diaz博士还是私人癌症基因组分析公司Personal Genome Diagnostics Inc.的创始人兼董事会成员，并于2010年至2016年4月担任总裁，首席执行官兼首席医疗官。他获得密歇根大学（the University of Michigan）的医学博士学位，在那里他也获得微生物学学士学位。
Luis Diaz, Jr.,M.D. —Dr. Diaz has served as the head of the solid tumor oncology division and a faculty member at the Memorial Sloan Kettering Cancer Center since December 2016, and was appointed to the National Cancer Advisory Board in September 2021. From 2004 to December 2016, Dr. Diaz was a faculty member and physician at Johns Hopkins University School of Medicine. He is also a founder and previously served as a board member, and from 2010 to April 2016, as president, chief executive officer and chief medical officer, of Personal Genome Diagnostics Inc., a private cancer genome analysis company, which was acquired by Labcorp in 2022. He received his M.D. from the University of Michigan, where he also received his B.A. in Microbiology. - LuisDiaz，Jr.，医学博士，迪亚兹博士自2016年12月起担任实体瘤肿瘤科主任兼纪念斯隆·凯特琳癌症中心教员。从2004年到2016年12月，Diaz博士是约翰霍普金斯大学医学院的教员和医生。Diaz博士还是私人癌症基因组分析公司Personal Genome Diagnostics Inc.的创始人兼董事会成员，并于2010年至2016年4月担任总裁，首席执行官兼首席医疗官。他获得密歇根大学（the University of Michigan）的医学博士学位，在那里他也获得微生物学学士学位。
- Luis Diaz, Jr.,M.D. —Dr. Diaz has served as the head of the solid tumor oncology division and a faculty member at the Memorial Sloan Kettering Cancer Center since December 2016, and was appointed to the National Cancer Advisory Board in September 2021. From 2004 to December 2016, Dr. Diaz was a faculty member and physician at Johns Hopkins University School of Medicine. He is also a founder and previously served as a board member, and from 2010 to April 2016, as president, chief executive officer and chief medical officer, of Personal Genome Diagnostics Inc., a private cancer genome analysis company, which was acquired by Labcorp in 2022. He received his M.D. from the University of Michigan, where he also received his B.A. in Microbiology.
- Luisa Salter Cid
-
Luisa Salter Cid博士—— Salter-Cid博士自2021年5月起担任旗舰开拓部门Pioneering Medicines的首席科学官。此前，Salter-Cid博士曾于2018年8月至2021年4月担任公共临床阶段生物制药公司Gossamer Bio, Inc.的首席科学官，并于2005年至2018年8月在百时美施贵宝担任越来越多的职务，最近担任副总裁兼免疫学、小分子免疫肿瘤学和基因组学发现负责人。Salter-Cid博士拥有里斯本大学生物学学士学位和迈阿密大学医学院免疫学博士学位。我们认为Salter-Cid博士有资格担任Jounce Therapeutics公司董事会成员，因为她在生命科学行业的领导经验和免疫肿瘤学方面的经验。
Luisa Salter Cid,Ph.D. —Dr. Salter-Cid has served as the Chief Scientific Officer of Pioneering Medicines, a division of Flagship Pioneering, since May 2021. Previously, Dr. Salter-Cid was the Chief Scientific Officer of Gossamer Bio, Inc., a public clinical-stage biopharmaceutical company, from August 2018 through April 2021, and worked at Bristol Myers Squibb in increasing positions of responsibility from 2005 to August 2018, most recently as Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery. Dr. Salter-Cid holds a B.S. in Biology from University of Lisbon and a Ph.D. in Immunology from the University of Miami School of Medicine. - Luisa Salter Cid博士—— Salter-Cid博士自2021年5月起担任旗舰开拓部门Pioneering Medicines的首席科学官。此前，Salter-Cid博士曾于2018年8月至2021年4月担任公共临床阶段生物制药公司Gossamer Bio, Inc.的首席科学官，并于2005年至2018年8月在百时美施贵宝担任越来越多的职务，最近担任副总裁兼免疫学、小分子免疫肿瘤学和基因组学发现负责人。Salter-Cid博士拥有里斯本大学生物学学士学位和迈阿密大学医学院免疫学博士学位。我们认为Salter-Cid博士有资格担任Jounce Therapeutics公司董事会成员，因为她在生命科学行业的领导经验和免疫肿瘤学方面的经验。
- Luisa Salter Cid,Ph.D. —Dr. Salter-Cid has served as the Chief Scientific Officer of Pioneering Medicines, a division of Flagship Pioneering, since May 2021. Previously, Dr. Salter-Cid was the Chief Scientific Officer of Gossamer Bio, Inc., a public clinical-stage biopharmaceutical company, from August 2018 through April 2021, and worked at Bristol Myers Squibb in increasing positions of responsibility from 2005 to August 2018, most recently as Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery. Dr. Salter-Cid holds a B.S. in Biology from University of Lisbon and a Ph.D. in Immunology from the University of Miami School of Medicine.
- Perry A. Karsen
-
Perry A. Karsen自2010年7月起担任首席营运官。他于2012年2月15日担任执行副总裁兼首席营运官。 他对所有营运操作负责，包括信息技术、企业和业务发展、技术操作和细胞治疗单位。 从2009年2月至2010年7月，他曾担任明珠治疗（一家私有的生物科技公司）的总裁兼首席执行官。从2004年到2009年，他担任高级副总裁兼全球业务发展部的总监，以总裁的身份负责亚太地区的新兴业务。在这之前，他曾在人类基因组科学Bristol-Myers-Squibb, Genentech and Abbott实验室担任行政职务。此外， 他还担任Pequot企业的普通合伙人。他是生物技术工业组织BIO的董事会成员；BayBio的董事会成员；生命科学基金会的董事会成员。另外，他还是Agios配药公司（一家私有的生物科技公司）的董事会成员。他在西北大学的凯洛格管理研究生院获得管理学学位， 在杜克大学获得生物学教学硕士学位，在伊利诺伊州厄巴纳大学获得生物科学学士学位。
Perry A. Karsen,—Mr. Karsen served as the chairman of Jounce Therapeutics, Inc. board of directors from April 2016 to June 2022. Mr. Karsen retired from Celgene Corporation at the end of 2015 and currently is a Senior Advisor at Samsara BioCapital as well as the Executive Chair of Autobahn Labs. He serves as the Chair of the Board of Directors of Nitrase Therapeutics (formerly Nitrome Biosciences), as Chair of the Board of Directors of Graphite Bio and on the Board of the Gladstone Foundation. Previously, Mr. Karsen served as a director of Jiya Acquisition Corp., a public blank check special purpose acquisition company affiliated with Samsara BioCapital, from November 2020 to September 2021, as well as on the boards of directors of Intellia Therapeutics, Inc. from April 2016 to December 2020, Voyager Therapeutics, Inc. from July 2015 to August 2019, and OncoMed Pharmaceuticals, Inc. from January 2016 to April 2019, each of which is a public life sciences company. Mr. Karsen received a Masters of Management from Northwestern University's Kellogg Graduate School of Management, a Masters of Arts in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign. - Perry A. Karsen自2010年7月起担任首席营运官。他于2012年2月15日担任执行副总裁兼首席营运官。 他对所有营运操作负责，包括信息技术、企业和业务发展、技术操作和细胞治疗单位。 从2009年2月至2010年7月，他曾担任明珠治疗（一家私有的生物科技公司）的总裁兼首席执行官。从2004年到2009年，他担任高级副总裁兼全球业务发展部的总监，以总裁的身份负责亚太地区的新兴业务。在这之前，他曾在人类基因组科学Bristol-Myers-Squibb, Genentech and Abbott实验室担任行政职务。此外， 他还担任Pequot企业的普通合伙人。他是生物技术工业组织BIO的董事会成员；BayBio的董事会成员；生命科学基金会的董事会成员。另外，他还是Agios配药公司（一家私有的生物科技公司）的董事会成员。他在西北大学的凯洛格管理研究生院获得管理学学位， 在杜克大学获得生物学教学硕士学位，在伊利诺伊州厄巴纳大学获得生物科学学士学位。
- Perry A. Karsen,—Mr. Karsen served as the chairman of Jounce Therapeutics, Inc. board of directors from April 2016 to June 2022. Mr. Karsen retired from Celgene Corporation at the end of 2015 and currently is a Senior Advisor at Samsara BioCapital as well as the Executive Chair of Autobahn Labs. He serves as the Chair of the Board of Directors of Nitrase Therapeutics (formerly Nitrome Biosciences), as Chair of the Board of Directors of Graphite Bio and on the Board of the Gladstone Foundation. Previously, Mr. Karsen served as a director of Jiya Acquisition Corp., a public blank check special purpose acquisition company affiliated with Samsara BioCapital, from November 2020 to September 2021, as well as on the boards of directors of Intellia Therapeutics, Inc. from April 2016 to December 2020, Voyager Therapeutics, Inc. from July 2015 to August 2019, and OncoMed Pharmaceuticals, Inc. from January 2016 to April 2019, each of which is a public life sciences company. Mr. Karsen received a Masters of Management from Northwestern University's Kellogg Graduate School of Management, a Masters of Arts in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign.
- Barbara Duncan
-
Barbara Duncan，自2009年5月起担任Atea Pharmaceuticals, Inc.的首席财务官，自2010年起担任Atea Pharmaceuticals, Inc.的财务主管。她有着超过15年的生命科学行业经验。Duncan女士于2009年5月至2016年6月在Intercept Pharmaceuticals，Inc.担任首席财务官兼财务主管。Duncan女士自2016年6月起担任Jounce Therapeutics，Inc.董事会成员，自2016年6月起担任Adaptimmune Therapeutics PLC.董事会成员，自2016年11月起担任Obseva S.A.董事会成员，自2017年6月起担任Ovid Therapeutics，Inc.董事会成员。自2001年至2009年4月，Duncan女士担任了DOV Pharmaceutical, Inc.， 或 DOV的首席财务官后来是首席执行官，该公司是一家生物制药公司，关注中枢神经系统异常，并于2010年被Euthymics Bioscience, Inc.收购。在加入DOV之前，从1998年8月至2001年8月，Duncan女士担任了Lehman Brothers Inc.的公司财务部担任副总裁，主要为生命科学和一般工业行业提供金融咨询服务。从1994年9月至1998年8月，Duncan女士担任了SBC Warburg Dillon Read, Inc.公司财务部的助理和董事，主要关注生命科学和一般工业行业的构建兼并、资产剥离和融资。1989年至1992年间，她也在PepsiCo, Inc.的国际审计部门工作；1986年至1989年间，也是Deloitte & Touche LLP审计部门的注册会计师。Duncan女士于1985年获得了Louisiana State University的学士学位，1994年获得了 Wharton School, University of Pennsylvania的工商管理硕士学位。她早前曾担任DOV的董事，目前是Edgemont Pharmaceuticals, LLC的董事，该公司是一家私人专业制药公司，主要关注神经科学领域。Duncan女士获得了路易斯安那州立大学的文学学士学位，宾夕法尼亚大学沃顿商学院的文学硕士学位。
Barbara Duncan,—Ms. Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc., a public biopharmaceutical company, from May 2009 to June 2016 and as treasurer from 2010 to June 2016. She serves as the chair of the board of directors of Fusion Pharmaceuticals Inc. and has been a member of the board of directors since October 2020. She has also served as a member of the board of directors of Halozyme, Inc. since February 2023, Adaptimmune Therapeutics plc since June 2016, Atea Pharmaceuticals, Inc. since October 2020 and Ovid Therapeutics, Inc. since June 2017, each of which is a public therapeutics company. She previously served on the board of public companies ObsEva SA from December 2016 to May 2021, Immunomedics, Inc. from March 2019 to October 2020, Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.) from June 2015 to February 2020 and Innoviva, Inc. from September 2016 to April 2018. Ms. Duncan holds an M.B.A. from the Wharton School of Business and a B.S. from Louisiana State University. - Barbara Duncan，自2009年5月起担任Atea Pharmaceuticals, Inc.的首席财务官，自2010年起担任Atea Pharmaceuticals, Inc.的财务主管。她有着超过15年的生命科学行业经验。Duncan女士于2009年5月至2016年6月在Intercept Pharmaceuticals，Inc.担任首席财务官兼财务主管。Duncan女士自2016年6月起担任Jounce Therapeutics，Inc.董事会成员，自2016年6月起担任Adaptimmune Therapeutics PLC.董事会成员，自2016年11月起担任Obseva S.A.董事会成员，自2017年6月起担任Ovid Therapeutics，Inc.董事会成员。自2001年至2009年4月，Duncan女士担任了DOV Pharmaceutical, Inc.， 或 DOV的首席财务官后来是首席执行官，该公司是一家生物制药公司，关注中枢神经系统异常，并于2010年被Euthymics Bioscience, Inc.收购。在加入DOV之前，从1998年8月至2001年8月，Duncan女士担任了Lehman Brothers Inc.的公司财务部担任副总裁，主要为生命科学和一般工业行业提供金融咨询服务。从1994年9月至1998年8月，Duncan女士担任了SBC Warburg Dillon Read, Inc.公司财务部的助理和董事，主要关注生命科学和一般工业行业的构建兼并、资产剥离和融资。1989年至1992年间，她也在PepsiCo, Inc.的国际审计部门工作；1986年至1989年间，也是Deloitte & Touche LLP审计部门的注册会计师。Duncan女士于1985年获得了Louisiana State University的学士学位，1994年获得了 Wharton School, University of Pennsylvania的工商管理硕士学位。她早前曾担任DOV的董事，目前是Edgemont Pharmaceuticals, LLC的董事，该公司是一家私人专业制药公司，主要关注神经科学领域。Duncan女士获得了路易斯安那州立大学的文学学士学位，宾夕法尼亚大学沃顿商学院的文学硕士学位。
- Barbara Duncan,—Ms. Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc., a public biopharmaceutical company, from May 2009 to June 2016 and as treasurer from 2010 to June 2016. She serves as the chair of the board of directors of Fusion Pharmaceuticals Inc. and has been a member of the board of directors since October 2020. She has also served as a member of the board of directors of Halozyme, Inc. since February 2023, Adaptimmune Therapeutics plc since June 2016, Atea Pharmaceuticals, Inc. since October 2020 and Ovid Therapeutics, Inc. since June 2017, each of which is a public therapeutics company. She previously served on the board of public companies ObsEva SA from December 2016 to May 2021, Immunomedics, Inc. from March 2019 to October 2020, Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.) from June 2015 to February 2020 and Innoviva, Inc. from September 2016 to April 2018. Ms. Duncan holds an M.B.A. from the Wharton School of Business and a B.S. from Louisiana State University.
高管简历
中英对照 | 中文 | 英文- Richard Murray
Richard Murray，自2014年7月以来，Murray一直担任Jounce Therapeutics，Inc.股份有限公司总裁、首席执行官以及Jounce ThrapeuticS，Inc.股份有限公司董事会成员。在加入Jounce之前，Murray博士于2009年至2014年6月期间担任默克公司（Merck&Co.）生物制品和疫苗研发高级副总裁，该公司是一家全球医疗保健公司，他负责生物制剂和疫苗的研发，包括默克的癌症免疫治疗管道。自2019年6月以来，他一直担任私人生物技术公司Platelet Biogenesis，Inc.的董事。Murray博士他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位，以及马萨诸塞大学（the University of Massachusetts，位于阿默斯特）的微生物学学士学位。
Richard Murray,Ph.D. —Dr. Murray has served as Jounce Therapeutics, Inc. president, chief executive officer and a member of Jounce Therapeutics, Inc. board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. Since June 2019, he has served as a director of Platelet Biogenesis, Inc., a private biotechnology company. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.- Richard Murray，自2014年7月以来，Murray一直担任Jounce Therapeutics，Inc.股份有限公司总裁、首席执行官以及Jounce ThrapeuticS，Inc.股份有限公司董事会成员。在加入Jounce之前，Murray博士于2009年至2014年6月期间担任默克公司（Merck&Co.）生物制品和疫苗研发高级副总裁，该公司是一家全球医疗保健公司，他负责生物制剂和疫苗的研发，包括默克的癌症免疫治疗管道。自2019年6月以来，他一直担任私人生物技术公司Platelet Biogenesis，Inc.的董事。Murray博士他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位，以及马萨诸塞大学（the University of Massachusetts，位于阿默斯特）的微生物学学士学位。
- Richard Murray,Ph.D. —Dr. Murray has served as Jounce Therapeutics, Inc. president, chief executive officer and a member of Jounce Therapeutics, Inc. board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. Since June 2019, he has served as a director of Platelet Biogenesis, Inc., a private biotechnology company. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
- Kim C. Drapkin
Kim C. Drapkin，自2015年8月起，Drapkin担任Jounce Therapeutics，Inc.股份有限公司首席财务官，自2013年2月起，担任Jounse Therapeunics，Inc.股份有限公司财务主管。2009年至2015年8月，Drapkin女士是KCD Financial LLC的所有者，在2012年至2015年间担任Jounce Therapeutics，Inc.临时首席财务官，并为众多生物技术公司提供咨询。Drapkin女士在PricewaterhouseCoopers LLP开始职业生涯，是一名注册会计师，拥有Babson学院的会计学士学位。
Kim C. Drapkin,—Ms. Drapkin has served as Jounce Therapeutics, Inc. chief financial officer since August 2015, and Jounce Therapeutics, Inc. treasurer since February 2013. From 2009 to August 2015, Ms. Drapkin was the owner of KCD Financial LLC, through which she served as Jounce Therapeutics, Inc. interim chief financial officer from 2012 to August 2015, and consulted for numerous biotechnology companies. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.- Kim C. Drapkin，自2015年8月起，Drapkin担任Jounce Therapeutics，Inc.股份有限公司首席财务官，自2013年2月起，担任Jounse Therapeunics，Inc.股份有限公司财务主管。2009年至2015年8月，Drapkin女士是KCD Financial LLC的所有者，在2012年至2015年间担任Jounce Therapeutics，Inc.临时首席财务官，并为众多生物技术公司提供咨询。Drapkin女士在PricewaterhouseCoopers LLP开始职业生涯，是一名注册会计师，拥有Babson学院的会计学士学位。
- Kim C. Drapkin,—Ms. Drapkin has served as Jounce Therapeutics, Inc. chief financial officer since August 2015, and Jounce Therapeutics, Inc. treasurer since February 2013. From 2009 to August 2015, Ms. Drapkin was the owner of KCD Financial LLC, through which she served as Jounce Therapeutics, Inc. interim chief financial officer from 2012 to August 2015, and consulted for numerous biotechnology companies. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.
- Elizabeth G. Trehu
Elizabeth G. Trehu，2015年11月，Trehu加入Jounce，出任Jounce Therapeutics，Inc.股份有限公司首席医疗官。在加入Jounce之前，Trehu博士于2012年至2015年11月担任生物技术公司Promedior，Inc.的首席医疗官。Trehu博士拥有纽约大学医学院的医学博士学位和普林斯顿大学的英语学士学位。
Elizabeth G. Trehu,M.D. —Dr. Trehu joined Jounce as Jounce Therapeutics, Inc. chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.- Elizabeth G. Trehu，2015年11月，Trehu加入Jounce，出任Jounce Therapeutics，Inc.股份有限公司首席医疗官。在加入Jounce之前，Trehu博士于2012年至2015年11月担任生物技术公司Promedior，Inc.的首席医疗官。Trehu博士拥有纽约大学医学院的医学博士学位和普林斯顿大学的英语学士学位。
- Elizabeth G. Trehu,M.D. —Dr. Trehu joined Jounce as Jounce Therapeutics, Inc. chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.
- Hugh M. Cole
Hugh M. Cole在2017年8月加入Jounce之前，于2014年3月至2017年6月担任肿瘤公司ARIAD Pharmaceuticals，Inc.的首席商务官，领导了多项业务开发交易。此前，Cole曾于2007年至2014年3月担任全球生物制药公司Shire plc的战略规划和项目管理高级副总裁。Cole先生在沃顿商学院（Wharton School of Business）获得了医疗管理和金融硕士学位，在哈佛大学（Harvard University）获得了化学学士学位。
Hugh M. Cole,—Prior to joining Jounce in August 2017, Mr. Cole served as chief business officer for ARIAD Pharmaceuticals, Inc., an oncology company, from March 2014 to June 2017, where he led numerous business development transactions. Previously, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, a global biopharmaceutical company, from 2007 to March 2014. Mr. Cole earned his M.B.A. in health care management and finance at the Wharton School of Business and his A.B. in chemistry from Harvard University.- Hugh M. Cole在2017年8月加入Jounce之前，于2014年3月至2017年6月担任肿瘤公司ARIAD Pharmaceuticals，Inc.的首席商务官，领导了多项业务开发交易。此前，Cole曾于2007年至2014年3月担任全球生物制药公司Shire plc的战略规划和项目管理高级副总裁。Cole先生在沃顿商学院（Wharton School of Business）获得了医疗管理和金融硕士学位，在哈佛大学（Harvard University）获得了化学学士学位。
- Hugh M. Cole,—Prior to joining Jounce in August 2017, Mr. Cole served as chief business officer for ARIAD Pharmaceuticals, Inc., an oncology company, from March 2014 to June 2017, where he led numerous business development transactions. Previously, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, a global biopharmaceutical company, from 2007 to March 2014. Mr. Cole earned his M.B.A. in health care management and finance at the Wharton School of Business and his A.B. in chemistry from Harvard University.